FDA proposes to cut comparative efficacy study requirements for most biosimilars
Regulatory NewsJoanne S. Eglovitch
Approval/marketing authorizationBiologics License Application (BLA)Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsManufacturingProduct developmentRegulatory Intelligence/PolicyRegulatory strategyUnited StatesUS Food and Drug Administration (FDA)